Lukas Käsmann1, Lisa Manig1, Stefan Janssen1, Dirk Rades2. 1. Department of Radiation Oncology, University of Lübeck, Lübeck, Germany. 2. Department of Radiation Oncology, University of Lübeck, Lübeck, Germany rades.dirk@gmx.net.
Abstract
BACKGROUND/AIM: To evaluate outcomes and toxicities of chemoradiation with a less intensive paclitaxel regimen for locally recurrent bladder cancer. PATIENTS AND METHODS: Three elderly patients received simultaneous chemoradiation for recurrent muscle-invasive bladder cancer. Chemotherapy included two courses (three times 25 mg/m2 over 1.5 weeks) of paclitaxel. Radiotherapy doses were 59.4 Gy to the bladder and 50.4 Gy to regional lymph nodes. Survival, local control and toxicities were retrospectively evaluated. RESULTS: One patient died after 71 months, two were alive after 69 and 98 months, respectively. No local recurrence was not observed. Five-year survival and local control rates were 100%. Two patients experienced grade 1 acute dysuria, one patient grade 1 diarrhea. Late toxicities were also mild; two patients had grade 1 dysuria. CONCLUSION: Chemoradiation with a less intensive paclitaxel regimen resulted in excellent 5-year results and was very well tolerated. It may be a reasonable option for elderly patients who cannot tolerate more intensive approaches. Copyright
BACKGROUND/AIM: To evaluate outcomes and toxicities of chemoradiation with a less intensive paclitaxel regimen for locally recurrent bladder cancer. PATIENTS AND METHODS: Three elderly patients received simultaneous chemoradiation for recurrent muscle-invasive bladder cancer. Chemotherapy included two courses (three times 25 mg/m2 over 1.5 weeks) of paclitaxel. Radiotherapy doses were 59.4 Gy to the bladder and 50.4 Gy to regional lymph nodes. Survival, local control and toxicities were retrospectively evaluated. RESULTS: One patient died after 71 months, two were alive after 69 and 98 months, respectively. No local recurrence was not observed. Five-year survival and local control rates were 100%. Two patients experienced grade 1 acute dysuria, one patient grade 1 diarrhea. Late toxicities were also mild; two patients had grade 1 dysuria. CONCLUSION: Chemoradiation with a less intensive paclitaxel regimen resulted in excellent 5-year results and was very well tolerated. It may be a reasonable option for elderly patients who cannot tolerate more intensive approaches. Copyright
Authors: Thorsten H Ecke; Christian Arndt; Carsten Stephan; Steffen Hallmann; Oliver Lux; Thomas Otto; Jürgen Ruttloff; Holger Gerullis Journal: Anticancer Res Date: 2015-05 Impact factor: 2.480
Authors: Claus Rödel; Gerhard G Grabenbauer; Reinhard Kühn; Thomas Papadopoulos; Jürgen Dunst; Martin Meyer; Karl M Schrott; Rolf Sauer Journal: J Clin Oncol Date: 2002-07-15 Impact factor: 44.544
Authors: Elizabeth A Guancial; Breton Roussel; Derek P Bergsma; Kevin C Bylund; Deepak Sahasrabudhe; Edward Messing; Supriya G Mohile; Chunkit Fung Journal: Clin Interv Aging Date: 2015-06-10 Impact factor: 4.458
Authors: Rachel A Mann; Ramón Virasoro; Jessica M DeLong; Rafael E Estrella; Merycarla Pichardo; Ramón Rodríguez Lay; Gustavo Espino; Joshua D Roth; Sean P Elliott Journal: Can Urol Assoc J Date: 2021-02 Impact factor: 1.862